Gliomatosis Cerebri Overview

Save information for later
Sign Up

Learn About Gliomatosis Cerebri

View Main Condition: Brain Tumor

What is the definition of Gliomatosis Cerebri?
Gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. It involves at least three sections (lobes) within the main part of the brain (cerebrum). It may also affect both sides of the cerebrum as well as the nerve cells within the brain (grey matter). There are two types of Gliomatosis cerebri. Type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. Signs and symptoms of Gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures.
What are the alternative names for Gliomatosis Cerebri?
  • Gliomatosis cerebri
Who are the top Gliomatosis Cerebri Local Doctors?
Katherine B. Peters
Elite in Gliomatosis Cerebri
Dr. Katherine B. Peters
Neurology
Elite in Gliomatosis Cerebri
Dr. Katherine B. Peters
Neurology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Katherine Peters is a Neurologist in Durham, North Carolina. Dr. Peters is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. Her top areas of expertise are Glioma, Gliomatosis Cerebri, Brain Tumor, and Astrocytoma. Dr. Peters is currently accepting new patients.

Henry S. Friedman
Elite in Gliomatosis Cerebri
Dr. Henry S. Friedman
Neurosurgery | Hematology | Oncology
Elite in Gliomatosis Cerebri
Dr. Henry S. Friedman
Neurosurgery | Hematology | Oncology

Duke Cancer Center Brain Tumor Clinic

20 Duke Medicine Cir, 
Durham, NC 
919-684-5301
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Friedman is a Neurosurgery specialist and a Hematologist in Durham, North Carolina. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Friedman is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Allan H. Friedman
Elite in Gliomatosis Cerebri
Dr. Allan H. Friedman
Neurosurgery
Elite in Gliomatosis Cerebri
Dr. Allan H. Friedman
Neurosurgery

Duke Cancer Center Brain Tumor Clinic

20 Duke Medicine Cir, 
Durham, NC 
919-684-5301
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Allan Friedman is a Neurosurgery provider in Durham, North Carolina. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, Awake Craniotomy, and Laminectomy. Dr. Friedman is currently accepting new patients.

View All Doctors
What are the latest Gliomatosis Cerebri Clinical Trials?
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2

Summary: Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be h...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor c...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center